2019
DOI: 10.1071/ah17031
|View full text |Cite
|
Sign up to set email alerts
|

Financial costs associated with monopolies on biologic medicines in Australia

Abstract: The aim of the study was to estimate the potential savings to the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) in 2015-16 if biosimilar versions of selected biologic medicines (biologics) had been available and listed on the PBS. The research involved retrospective analysis of Australian Medicare expenditure data and PBS price data from 2015-16 for biologics, for which biosimilar competition may be available in future, listed on the PBS. Australian Government … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
28
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 18 publications
(29 citation statements)
references
References 12 publications
(24 reference statements)
0
28
0
Order By: Relevance
“…With several biologics reaching patent expiry and the end of exclusivity periods, there is an increasing development and adoption of biosimilar medicines, which have the potential to improve affordability and access to therapy . It is estimated that the Australian Government's annual spending of AU$2.2 billion on biologics could be decreased by up to 24% through the successful uptake of biosimilar medicines . Although the predominant focus of current literature has been on physicians' awareness and confidence of biosimilars, an effective introduction of biosimilars requires an understanding of patient attitudes of these medicines.…”
Section: Study Cohort Characteristicsmentioning
confidence: 99%
“…With several biologics reaching patent expiry and the end of exclusivity periods, there is an increasing development and adoption of biosimilar medicines, which have the potential to improve affordability and access to therapy . It is estimated that the Australian Government's annual spending of AU$2.2 billion on biologics could be decreased by up to 24% through the successful uptake of biosimilar medicines . Although the predominant focus of current literature has been on physicians' awareness and confidence of biosimilars, an effective introduction of biosimilars requires an understanding of patient attitudes of these medicines.…”
Section: Study Cohort Characteristicsmentioning
confidence: 99%
“…Expansive intellectual property rights in trade agreements, which include extending pharmaceutical monopolies, can keep medicine prices higher for longer 21 . New biologic medicines to treat cancer and other NCDs are increasingly expensive – in 2015–16 alone Australia spent more than two billion dollars on biologics 22 . More than 367 million would have been saved if cheaper biosimilars (i.e.…”
Section: Trade Agreements Are Structural Drivers Of Ncdsmentioning
confidence: 99%
“…Apart from cost savings by virtue of their lower development costs, biosimilars can also affect the pricing of the reference biologic through competition. For example, the price of filgrastim in Australia fell by 62% (over 6 years) following the entry of three competing biosimilars into the market . Approximately half (52%) of the total PBS expenditure on filgrastims in 2015–2016 was for the biosimilar versions, indicating a substantial uptake of these biosimilars …”
Section: Impact Of Biosimilars In Australiamentioning
confidence: 99%
“…In November 2017, the first rituximab biosimilar, Riximyo (Sandoz GmbH, Kundl, Austria), was approved by the TGA for the treatment of B‐cell non‐Hodgkin lymphoma and chronic lymphocytic leukaemia . Of note, the PBS expenditure (as publicly disclosed) for rituximab during the 2015–2016 financial year was ~AU$270 million . Given the recent entry of the rituximab biosimilar into the Australian market, the impact of its approval on pricing can only be estimated at this stage.…”
Section: Impact Of Biosimilars In Australiamentioning
confidence: 99%
See 1 more Smart Citation